-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
FNC-TP
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/2457357-99-0.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 2457357-99-0 |
| Description | FNC-TP is the intracellular active form of FNC which is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and HCV. |
Product Information
| Synonyms | RO-0622-TP |
| IUPAC Name | [[(2R,3R,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-azido-4-fluoro-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate |
| Molecular Weight | 526.16 |
| Molecular Formula | C9H14FN6O13P3 |
| Canonical SMILES | C1=CN(C(=O)N=C1N)C2C(C(C(O2)(COP(=O)(O)OP(=O)(O)OP(=O)(O)O)N=[N+]=[N-])O)F |
| InChI | InChI=1S/C9H14FN6O13P3/c10-5-6(17)9(14-15-12,27-7(5)16-2-1-4(11)13-8(16)18)3-26-31(22,23)29-32(24,25)28-30(19,20)21/h1-2,5-7,17H,3H2,(H,22,23)(H,24,25)(H2,11,13,18)(H2,19,20,21)/t5-,6-,7+,9+/m0/s1 |
| InChIKey | BRACSMALKQTJNX-XZMZPDFPSA-N |
| Purity | 99% |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | White to off-white (Solid) |
| Storage | -20°C, protect from light * In solvent : -80°C, 6 months -20°C, 1 month (protect from light) |
| Complexity | 1030 |
| Exact Mass | 525.98157368 |
| In Vitro | FNC (0.1-10 nM; 24-240 h) is found mainly to accumulate in these HIV-1 target cells, and the retention of FNC-TP is 2-4 times higher than in other types of cells. |
| In Vivo | NC (1-6 mg/kg; a single p.o.) could enter rhesus macaque PBMCs and form the active nucleoside triphosphate FNC-TP. |
| Target | Reverse Transcriptase; HIV; HBV; HCV |
| XLogP3-AA | -4.6 |